PTPN22 and neoplasm: There are several other CPHPs found in the literature that can target tumor vasculature (e.g., iRGD [184], tumor lymphatics (e.g., LyP1) [185], or certain specific cancer cell types (e.g., melanoma-targeting Pep42) [186].